Mechanisms of action by which addressing each risk factor can potentially reduce dementia risk. (WHO)
Posted on 09/22/2026 8:06:12 PM PDT by SeekAndFind
Dementia research has reached a profound turning point.
Alzheimer's disease was once considered 'untreatable', but that is not the universal rule any longer, according to this year's World Alzheimer Report.
In the past five years alone, novel drugs have been shown to modestly slow decline in early Alzheimer's, while growing evidence suggests some dementia cases could potentially be delayed or prevented through risk reduction.
Today, hundreds of clinical trials worldwide are now investigating possible medicines, new diagnostic options, and lifestyle interventions to identify, treat, or delay cognitive decline.
The possibility of a cure is still far away, but it "feels like a more palpable prospect than ever before," according to the 2026 World Alzheimer Report, coauthored by Alzheimer's Disease International (ADI) and leading health journalist Paul Gallagher.
"After decades during which dementia was widely regarded as an inevitable consequence of old age and neurodegeneration with few therapeutic options beyond symptom management, research has entered an era of unprecedented activity," reads the report.
"Alzheimer's disease is no longer universally described as untreatable; instead, it is increasingly viewed as a condition for which earlier diagnosis, better understanding of disease biology, and a wider range of interventions may collectively improve outcomes."
ADI calls itself the 'global voice of dementia'. It is a worldwide federation of dementia associations in official relations with the World Health Organization (WHO).
Every year since 2009, the ADI has published a report on dementia research, and each year, it covers a different topic.
This year's report is titled 'A New Era in Dementia Clinical Trials', and it argues that dementia research has now entered a period of remarkable scientific momentum.
This moment is akin to oncology in the 1990s, argue the authors, when the first generation of cancer therapies, while imperfect, opened the door to effective drug combos, precision medicine, and earlier intervention.
"For now, there is no single breakthrough to rival the discovery of penicillin or the advent of statins," argues the report.
"Instead, there is something quieter… It is a shift from cure to prevention, from molecule to lifestyle, from inevitability to possibility."
As populations age worldwide, some estimates predict there will be 139 million people living with dementia by 2050.
Even modest delays in the onset of cognitive decline could translate to millions fewer cases.
Just recently, for instance, WHO published new guidelines on how to reduce the risk of dementia.
According to emerging research, as many as 45 percent of dementia cases could potentially be prevented or delayed by addressing 14 modifiable risk factors across the lifespan.
These include hypertension, depression, physical inactivity, smoking, diabetes, excessive alcohol use, and high cholesterol.
Mechanisms of action by which addressing each risk factor can potentially reduce dementia risk. (WHO)
Dementia clinical trials also stand at an important moment in history, according to the report.
Between 2000 and 2020, more than 99 percent of experimental drugs failed in clinical trials.
The recent arrival of the drugs donanemab and lecanemab was a huge moment, argues Cath Mummery, director of the UK's Dementia Trials Network.
These were the first fully approved drugs shown to modestly slow the progression of early Alzheimer's disease, rather than merely treating its symptoms.
"What you really hoped for was a bigger effect [on patients], but it was a huge moment because it showed you could change the course of the disease," says Mummery in the report.
"That's the foundation. It's the first brick, and there's an awful lot to build on."
Today, not all researchers are convinced that donanemab and lecanemab lead to clinically meaningful benefits; for instance, they don't seem to work the same for every patient or in every part of the brain.
But the approval of these two drugs represents a positive turn of events, which has changed our expectations for what dementia research may achieve, argues the new report.
Over the past decade, the number of candidate medicines under investigation for dementia has increased by around 40 percent.
Currently, researchers are evaluating 158 potential therapies across 192 clinical trials worldwide.
This year alone, we should get results from eight Phase III trials – which rigorously test treatments on a large number of people in comparison to standard care.
A lot of these drugs are already approved for use in humans. In fact, more than a third of dementia drugs currently in the pipeline were originally developed for other conditions.
Explanation for phase III clinical trials. (ADI 2026 World Alzheimer Report)
Unfortunately, however, many patients in the early stages of cognitive decline do not know these possibilities exist.
Neuroradiologist Emer MacSweeney told ADI: "The biggest mistake that's happening at the minute is people who are clearly, obviously, most likely in the early stages of Alzheimer's, being ignored and completely missed… because that window of opportunity is really small for treatment."
MacSweeney says patients are often uninformed about clinical trials or how to access new medications.
"This is a pandemic," MacSweeney emphasizes. "We need a change in mindset in the medical profession to ensure more people are told about clinical trials and supported to join them. We need action, not rhetoric."
One of the biggest potholes in the road is diagnosis.
A new generation of treatments that can potentially slow the decline of memory and thinking is all well and good, but these medicines are only useful if they actually get to patients.
In the United Kingdom, for instance, only about 2 percent of people diagnosed with Alzheimer's have access to a gold-standard diagnostic test, according to a study co-led by Jonathan Schott, Chief Medical Officer at Alzheimer's Research UK.
Blood tests that look for biomarkers of dementia could be a solution.
While these new tools look promising in initial studies, they still need to be tested at a population level to see if they can accurately identify those individuals with early signs of cognitive decline.
"A breakthrough drug means little if the majority of people living with dementia are never identified in the first place," argues the ADI report.
"In that sense, the future of dementia care may depend as much on family doctors in Havana, Lima, or Bangalore as on billion-dollar laboratories in California."
According to the report, there is genuine cause for optimism. Now we just need to make sure that scientific progress is matched by clinical progress.
"The challenge for the next decade is to ensure that taking part in dementia research no longer depends on persistence or good fortune," concludes the report, "but becomes a realistic opportunity for everyone who wishes to consider it."
The report is published on the ADI website.
This article was fact-checked by Peter Dockrill and edited by Peter Dockrill. While we pride ourselves on our process, we are only human. If you spot a mistake, please let us know.
Dear FRiends,
We need your continuing support to keep FR funded. Your donations are our sole source of funding. No sugar daddies, no advertisers, no paid memberships, no commercial sales, no gimmicks, no tax subsidies. No spam, no pop-ups, no ad trackers.
If you enjoy using FR and agree it's a worthwhile endeavor, please consider making a contribution today:
Click here: to donate by Credit Card
Or here: to donate by PayPal
Or by mail to: Free Republic, LLC - PO Box 9771 - Fresno, CA 93794
Thank you very much and God bless you,
Jim
Schools are no longer teaching critical thinking. Will that mean those students will have higher levels of dementia?
I heard just recently about a woman with Alzheimers who was given an experimental drug, and not only improved...she recovered some memory. If true, amazing.
There is hope for this terrible, terrible thing.
My cousin just passed after 7 years of progressing Alzheimers. And he died from Alzheimers. His brain could no longer message the diaphragm and lungs to function. He died literally of suffocation.
I want a pill dadburnit. I don’t want to give up drinking, cigars a d sugary snacks and the last thing I want to do is exercise. I tried exercise a long time ago and it was boring and hurts. Huey Lewis was right. I need a new drug.
Not all dementia is Alzheimer’s. For example, dementia can be caused as a side effect of prescription drugs, and it can be “cured” by stopping those drugs.
Bkmk
Cause of death in such cases is often “adult failure to thrive.”
The COVID jab is linked.....
I’m wondering if people are being diagnosed as having Alzheimer’s because there’s a lot of money to be made for pharma. If you or someone you know is tagged with this lucrative (for pharma) disease, DON’T ACCEPT IT AS GOSPEL.
This week I was reading about Kris Kristofferson, who was diagnosed with having Alzheimer’s. His wife was not a dummy — they met when she was in law school. She wasn’t ready to accept Alzheimer’s.
AI: “Kris Kristofferson was initially misdiagnosed with Alzheimer’s disease before discovering his severe memory loss was actually caused by chronic Lyme disease.
The Misdiagnosis -
Symptoms: In his late 70s, country music legend Kris Kristofferson suffered from severe memory loss, confusion, and muscle pain.
Initial Belief: Doctors thought he had Alzheimer’s disease or dementia caused by sports concussions from his younger days playing football and boxing.
Medications: He spent years taking unhelpful medications for Alzheimer’s and depression that caused unwanted side effects.
Lisa’s Advocacy and Breakthrough -
Pushing for Answers: His wife, Lisa Meyers, refused to accept the terminal Alzheimer’s prognosis.
The Tick-Borne Diagnosis: In 2016, a medical specialist tested him for Lyme disease, and the result came back positive.
Suspected Source: Lisa believed he contracted the infection years earlier while crawling on the forest floor for six weeks in Vermont while filming the 2006 movie Disappearances.
Recovery and Later Life -
Treatment: After stopping his dementia drugs and completing a three-week course of targeted antibiotic treatments, his memory and mood improved dramatically.
Return to Music: Kristofferson regained his clarity, returned to the stage to perform, and lived a full life for several more years before passing away peacefully on September 28, 2024, at the age of 88”
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.